Cipla launches rapid antigen detection test for COVID-19 diagnosis
Cipla Limited today announced its partnership with Premier Medical Corporation Private Limited for commercialisation of rapid antigen test kits for COVID-19 in India.
CIPtest is a reliable high-performing kit that has been validated & approved by Indian Council of Medical Research (ICMR) and is found to have a specificity of 98.09 per cent and a sensitivity of up to 75 per cent. Besides being a rapid test with a quick turnaround time, it enables easy interpretation of results without the need for any additional instrument. The company will commence the supply of the kits from this week. Cipla’s expansive distribution network will help in the smooth distribution of the kits across the country.
This is Cipla’s second launch in the diagnostic space. The company will look after the marketing & distribution of the rapid antigen detection test for the qualitative detection of SARS-CoV-2 antigen.
Cipla is a global pharmaceutical company focussed on agile & sustainable growth, complex generics, and deepening portfolio in the markets of India, South Africa, North America, and key regulated & emerging markets. Formed in the year 1935, Cipla currently has 46 manufacturing sites around the world with a range of 1,500+ products.
At 11.31 am on Wednesday, its stock was up by Rs 5.35 or 0.68 per cent from its previous close and was trading at Rs 787.